MTOR and cytomegalovirus infection: Modulation of immunosuppressive treatment by decreasing the immunosuppressant doses or switching to mTOR inhibitors or CSA may be beneficial for patients suffering from refractory or resistant CMV infection qualified for virus specific therapies, as was demonstrated in SOT recipients [51, 52, 53, 54, 55].